Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation

Fig. 1

SU11274 and crizotinib inhibit melanoma cell proliferation. a Flow cytometry analysis of four different human melanoma cell lines confirmed high expression of c-Met receptor. Anti-human c-Met-PE (Met, HGFR) antibody was used to detect positive cells, DAPI was used as a viability counterstain. b Phosphorylation status of c-Met was examined by western blot. Tyr1349 is phosphorylated in A375 and Rel3, SU11274 further increased phosphorylation in A375. cd Adherent melanoma cells exhibited similar IC50 values for c-Met inhibitors SU11274 or crizotinib. Relative viability was determined by luminescent viability assay on day 3. Values were calculated from the quadruplicates as means + SD

Back to article page